BioAge Labs initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of BioAge Labs (BIOA) with an Outperform rating and $60 price target. The firm is optimistic on the company’s lead asset BGE-102’s NLRP3 inhibition. The “highly validated target has recently garnered significant attention” for its potential in cardiovascular risk reduction following the “encouraging” Phase 2 data from Ventyx Biosciences (VTYX), the analyst tells investors in a research note. Oppenheimer highlights BGE-102’s “critical differentiation” versus adjacent NLRP3s and interleukin programs.